Ñз¢Ï£Íû | Á¢ÒìÒ©ÂíÀ´Ëá°¢·¥Çú²´ÅÁÖÎÁƳÉÈËÂýÐÔITPÖйú¢óÆÚÑо¿Ð§¹ûÕýʽ¼û¿¯£¡
ÂíÀ´Ëá°¢·¥Çú²´ÅÁÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Òý½øµÄС·Ö×ÓÁ¢ÒìÒ©¡¢ÐÂÒ»´úѪС°åÌìÉúËØÊÜÌ弤¶¯¼Á£¨TPO-RA£©£¬£¬£¬£¬£¬£¬£¬£¬ÓÚ2019Äê5Ô»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©ÊÚÓèÓÅÏÈÉóÆÀ×ʸñ£¬£¬£¬£¬£¬£¬£¬£¬2020Äê4Ô±»Åú×¼ÓÃÓÚÔñÆÚÐÐÕï¶ÏÐÔ²Ù×÷»òÕßÊÖÊõµÄÂýÐԸβ¡£¡£¡£ ¡£¡£¨CLD£©Ïà¹ØѪС°åïÔÌÖ¢µÄ³ÉÄ껼ÕßÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬ÆäÓÃÓÚÖÎÁƶԼÈÍùÖÎÁÆ·´Ó¦²»¼ÑµÄ³ÉÈËÂýÐÔÃâÒßÐÔѪС°åïÔÌÖ¢£¨ITP£©µÄ˳Ӧ֢ÏÖÔÚÒÑÔÚÃÀ¹úºÍÅ·ÖÞ»ñÅú¡£¡£¡£ ¡£¡£2023Äê9ÔÂ11ÈÕ£¬£¬£¬£¬£¬£¬£¬£¬ÂíÀ´Ëá°¢·¥Çú²´ÅÁÖÎÁƳÉÈËÂýÐÔITPµÄÖйú¾³ÄÚ¢óÆÚÖ÷ÒªÑо¿Ð§¹ûÕýʽ½ÒÏþÓÚ¹ú¼ÊSCIÆÚ¿¯Research and Practice in Thrombosis and Haemostasis£¨IF=4.6£©1¡£¡£¡£ ¡£¡£
ȪԴ£ºÆÚ¿¯½ÒÏþÒ³Ãæ
Ñо¿Éè¼Æ
Ñо¿ÓÉ3¸ö½×¶Î×é³É£ºÉ¸Ñ¡ÆÚ£¨4ÖÜ£©¡¢½¹µãÖÎÁÆÆÚ£¨6ÖÜ£©ºÍÀ©Õ¹ÖÎÁÆÆÚ£¨20ÖÜ£©¡£¡£¡£ ¡£¡£È·ÕïΪÂýÐÔÔ·¢ITP£¨Ò»Á¬Ê±¼ä¡Ý12¸öÔ£©ºÍѪС°å¼ÆÊý¾ùÖµ<30¡Á109/LµÄ18-80ËêÊÜÊÔÕßÒÔ2:1µÄ±ÈÀýËæ»ú½ÓÊÜÂíÀ´Ëá°¢·¥Çú²´ÅÁ£¨Æðʼ¼ÁÁ¿20 mg£©»òο½å¼ÁÖÎÁÆ6ÖÜ¡£¡£¡£ ¡£¡£Íê³É6Öܽ¹µãÖÎÁÆÆں󣬣¬£¬£¬£¬£¬£¬£¬¼°¸ñµÄÊÜÊÔÕß½«½øÈëΪÆÚ20ÖܵÄÂíÀ´Ëá°¢·¥Çú²´ÅÁ¿ª·Å±êÇ©À©Õ¹ÖÎÁÆÆÚ¡£¡£¡£ ¡£¡£Ö÷ÒªÑо¿ÖÕµãÊÇÔÚûÓе÷½âÖÎÁÆÇéÐÎÏ£¬£¬£¬£¬£¬£¬£¬£¬½¹µãÖÎÁÆÆÚµÚ6ÖÜʱѪС°å¼ÆÊý¡Ý50¡Á109/LµÄ±¬·¢ÑªÐ¡°å·´Ó¦µÄÊÜÊÔÕß±ÈÀý¡£¡£¡£ ¡£¡£
ͼ1 ½¹µãÖÎÁÆÆÚ(A)ºÍÀ©Õ¹ÖÎÁÆÆÚ(B)µÄÑо¿Éè¼Æ
AVA, °¢·¥Çú²´ÅÁ; EOT, ÖÎÁÆ¿¢ÊÂ; ITP, ÃâÒßÐÔѪС°åïÔÌÖ¢; PBO, ο½å¼Á; qd, ÌìÌìÒ»´Î
Ñо¿Ð§¹û
¹²74ÀýÊÜÊÔÕßÔÚ½¹µãÖÎÁÆÆÚËæ»ú½ÓÊÜÂíÀ´Ëá°¢·¥Çú²´ÅÁ£¨n=48£©»òο½å¼Á£¨n=26£©ÖÎÁÆ¡£¡£¡£ ¡£¡£»£»£»£»£»ùÓÚÈ«ÆÊÎö¼¯µÄÆÊÎöЧ¹ûÏÔʾ£¬£¬£¬£¬£¬£¬£¬£¬ÖÎÁÆ6Öܺ󣬣¬£¬£¬£¬£¬£¬£¬ÂíÀ´Ëá°¢·¥Çú²´ÅÁ×éµÄÊÜÊÔÕßѪС°å·´Ó¦ÂÊΪ77.1% £¨95% CI£º62.7%, 88.0%)£¬£¬£¬£¬£¬£¬£¬£¬Î¿½å¼Á×éΪ7.7% (95% CI£º1.0%, 25.1%)£¬£¬£¬£¬£¬£¬£¬£¬Á½×é·´Ó¦ÂʲîֵΪ69.4% (95% CI£º56.2%, 86.3%)¡£¡£¡£ ¡£¡£Ñо¿µÖ´ïÖ÷ÒªÑо¿Öյ㣬£¬£¬£¬£¬£¬£¬£¬Ð§¹ûÖ§³ÖÂíÀ´Ëá°¢·¥Çú²´ÅÁÓÅÓÚο½å¼Á¡£¡£¡£ ¡£¡£ÔÚËùÓÐÔ¤ÏȽç˵µÄÑÇ×é(Æ¢ÇгýÊõ״̬¡¢»ùÏßѪС°å¼ÆÊý¡¢»ùÏßITPÅãͬÓÃÒ©)ºÍʺóÑÇ×é(¼ÈÍùTPO-RAÓÃÒ©)ÆÊÎöЧ¹ûÓëÖ÷ÒªÑо¿Ð§¹ûÒ»Ö£¨Í¼2£©¡£¡£¡£ ¡£¡£Õû¸öÑо¿Ê±´ú½ÓÊÜÂíÀ´Ëá°¢·¥Çú²´ÅÁÖÎÁÆÊÜÊÔÕßµÄƽ¾ùÀÛ»ýѪС°å·´Ó¦Ê±¼äΪ15.3ÖÜ¡£¡£¡£ ¡£¡£
ͼ2 ¹ØÓÚÖÎÁƵÚ6ÖÜʱÓÐѪС°å·´Ó¦µÄÊÜÊÔÕß±ÈÀýµÄÑÇ×éÆÊÎö
ͼ3 ÔÚ6Öܽ¹µãÖÎÁÆÆÚÖУ¬£¬£¬£¬£¬£¬£¬£¬Á½×éѪС°å¼ÆÊý½Ï»ùÏßˮƽµÄƽ¾ù(±ê×¼Îó²î)ת±ä
ÔÚ½¹µãÖÎÁÆÆÚ£¬£¬£¬£¬£¬£¬£¬£¬ÂíÀ´Ëá°¢·¥Çú²´ÅÁ×éºÍο½å¼Á×éÖÎÁÆʱ´ú²»Á¼ÊÂÎñ£¨TEAE£©±¬·¢ÂÊ»®·ÖΪ85.4%ºÍ76.9%£¬£¬£¬£¬£¬£¬£¬£¬Á½×é»®·ÖÓÐ2
(4.2%) ºÍ 5 (19.2%)Àý»¼Õß±¬·¢ÓëÖÎÁÆÒ©ÎïÎ޹صÄ3¼¶¼°ÒÔÉϲ»Á¼·´Ó¦ÊÂÎñ¡£¡£¡£ ¡£¡£½¹µãÖÎÁƽ׶Î̻¶µ÷½âºó°¢·¥Çú²´ÅÁ×éºÍο½å¼Á×éÖÎÁÆÏà¹ØÐÔ²»Á¼ÊÂÎñ±¬·¢ÂÊ»®·ÖΪ0.021/»¼ÕßÈÕ£¬£¬£¬£¬£¬£¬£¬£¬0.009/»¼ÕßÈÕ¡£¡£¡£ ¡£¡£
Ñо¿½áÂÛ
ÔÚÖйúÂýÐÔITP³ÉÈË»¼ÕßÖУ¬£¬£¬£¬£¬£¬£¬£¬ÂíÀ´Ëá°¢·¥Çú²´ÅÁÖÎÁÆ6ÖܺóѪС°å¼ÆÊýµÖ´ï¡Ý50 ¡Á 109µÄ»¼Õ߸ߴï77.1%£¬£¬£¬£¬£¬£¬£¬£¬ÏÔÖøÓÅÓÚο½å¼Á¡£¡£¡£ ¡£¡£ÂíÀ´Ëá°¢·¥Çú²´ÅÁ×ÜÌåÄÍÊÜÐÔÓÅÒ죬£¬£¬£¬£¬£¬£¬£¬ÔÚ½¹µãÖÎÁÆÆÚûÓÐÒòÖÎÁÆÏà¹ØµÄTEAE¶øÖÐÖ¹ÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬Ò²Ã»ÓÐÖÎÁÆÏà¹ØµÄÑÏÖز»Á¼ÊÂÎñ±¨µÀ¡£¡£¡£ ¡£¡£
ÆÚ¿¯ÏÈÈÝ£º
2022ÄêÓ°ÏìÒò×Ó£º4.6 ???ÖпÆÔºSCI£¨2022Äê12ÔÂÉý¼¶°æ£©2ÇøÆÚ¿¯
Research and Practice in Thrombosis and HaemostasisÊǹú¼ÊѪ˨ÓëֹѪѧ»á£¨the International Society on Thrombosis and Haemostasis, ISTH£©µÄ¹Ù·½ÆÚ¿¯£¬£¬£¬£¬£¬£¬£¬£¬Ö÷Òª¿¯µÇѪ˨Ðγɡ¢Ö¹Ñª¡¢Ñª¹Ü¼²²¡¼°Ïà¹ØÁìÓòµÄ»ù´¡¡¢×ª»¯¡¢ÁÙ´²ºÍÉú³Ý/¹«¹²ÎÀÉúÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬£¬£¬£¬Í¬Ê±Ò²¿¯µÇ°üÀ¨Õë¶ÔÐÂÐÍÕչ˻¤Ê¿ºÍ¶¨ÐÔÑо¿ÔÚÄÚµÄÖÊÁ¿¡¢Ð§¹û¡¢Èö²¥ºÍʵÑé¿ÆѧÏà¹ØµÄÂÛÎÄ¡£¡£¡£ ¡£¡£
ÉóÅúºÅ£ºNP-MA-20230915-CN-AVA-00006
²Î¿¼ÎÄÏ×£º
-
1.???? Heng Mei, et al. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Res Pract Thromb Haemost. 2023;7:e102158.
